| scholarly article | Q13442814 |
| P50 | author | Prokar Dasgupta | Q16728391 |
| Arun Sahai | Q79805503 | ||
| P2093 | author name string | C Dowson | |
| M S Khan | |||
| J Watkins | |||
| P2860 | cites work | Systematic review and meta-analysis of methods of diagnostic assessment for urinary incontinence | Q36611132 |
| Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. | Q37281713 | ||
| Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder | Q37314884 | ||
| Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats | Q45062115 | ||
| Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study | Q46090892 | ||
| Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats | Q46566035 | ||
| Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection | Q46601229 | ||
| Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. | Q46644837 | ||
| Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation | Q46816115 | ||
| Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks | Q47942659 | ||
| Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. | Q51347644 | ||
| Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. | Q51811543 | ||
| Reproducibility of cystometry in overactive detrusor. | Q52143679 | ||
| Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. | Q52937783 | ||
| Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. | Q53122363 | ||
| Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. | Q53191975 | ||
| Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. | Q53315918 | ||
| The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 | ||
| The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. | Q54578342 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 698-704 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | International Journal of Clinical Practice | Q15758177 |
| P1476 | title | The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial | |
| P478 | volume | 65 |
| Q26764765 | Botulinum toxin A for the Treatment of Overactive Bladder |
| Q89834897 | Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis |
| Q38042335 | Interstitial cystitis and the overlap with overactive bladder. |
| Q38993067 | Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis. |
| Q91801231 | The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis |
| Q38200003 | The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis |
| Q90394415 | Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside |
Search more.